info@seagull-health.com
SeagullHealth
语言:
search
new
Indications for Meloxicam
502
Article source: Seagull Pharmacy
Nov 10, 2025

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) first approved for marketing in the United States in 2000. As a potent inhibitor of cyclooxygenase (COX-1 and COX-2), it exerts analgesic, anti-inflammatory, and antipyretic effects by blocking the production of prostaglandins during the inflammatory process.

Indications for Meloxicam

Therapeutic Areas in Adults

Meloxicam is primarily indicated for the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA) in adults.

For osteoarthritis, this medication effectively relieves symptoms such as joint pain, stiffness, and functional impairment.

In the treatment of rheumatoid arthritis, Meloxicam can significantly improve key indicators including morning stiffness duration, joint swelling, and pain scores.

Indications in Pediatric Patients

Meloxicam is also indicated for adolescent patients with juvenile rheumatoid arthritis (JRA) who have a body weight of ≥ 60 kg, specifically targeting patients with oligoarticular or polyarticular disease course.

Contraindications for Use

Patients with a known allergy to Meloxicam or any component of the medication.

Patients with a history of asthma, urticaria, or other allergic-type reactions.

Patients in the perioperative period of coronary artery bypass grafting (CABG) surgery.

Specifications and Properties of Meloxicam

Dosage Specifications

Meloxicam is available as pale yellow tablets in two strengths: 7.5 mg and 15 mg.

The 7.5 mg tablets are round, biconvex, and uncoated. One side is embossed with the Boehringer Ingelheim logo, and the other side is embossed with the letter "M".

The 15 mg tablets are oval, biconvex, and uncoated. One side is embossed with the number "15", and the other side is embossed with the letter "M".

Drug Composition

Active ingredient: Meloxicam. Its chemical name is 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide, with a molecular weight of 351.4.

Molecular formula: C₁₄H₁₃N₃O₄S₂.

Excipients: Colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium citrate dihydrate.

Physicochemical Properties

Meloxicam is a pale yellow solid. It is practically insoluble in water, highly soluble in strong acids and strong alkalis, and slightly soluble in methanol.

The apparent partition coefficient of this substance in n-octanol/buffer (pH 7.4) is 0.1, and its pKa values are 1.1 and 4.2.

Storage Methods for Meloxicam

Storage Environment Requirements

Meloxicam should be stored at room temperature between 20°C and 25°C (68°F and 77°F), with short-term storage allowed within the range of 15°C to 30°C (59°F to 86°F).

Packaging Protection Measures

The medication must be stored in its original packaging.

Store in a dry place: Ensure the storage environment is dry.

Airtight container: Use sealed containers for repackaging (if necessary).

Protect from light: Prevent direct exposure to sunlight.

Handling Precautions

Always keep the tablets in their original moisture-proof packaging.

Remove from the packaging only before the first use.

Keep out of the reach of children to ensure safe storage of the medication.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
How to Purchase Meloxicam
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of osteoarthritis (OA), rheumatoid arthritis (RA), and juvenile idiopathic arthritis (JRA) in patients with a bod...
Standard Usage Instructions
Wayrilz (Rezabrutinib) is a kinase inhibitor that primarily acts on Bruton's Tyrosine Kinase (BTK). First approved in the United States in 2025, this medication is indicated for the treatment of p...
Indications for Wayrilz (Rezabrutinib)
Wayrilz (Rezabrutinib) is a novel kinase inhibitor, first approved for marketing in the United States in 2025. As a small-molecule covalent reversible inhibitor targeting Bruton's Tyrosine Kinase ...
What Are the Side Effects of Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)?
Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) is a triple-combination therapy medication containing fluticasone furoate (an inhaled corticos...
Administration for Meloxicam
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. First approved in the United States in 2000, it is indicated for the treatment of...
Indications for Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)
Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) is a triple-combination preparation containing fluticasone furoate (an inhaled corticosteroid)...
How to Purchase Wayrilz (Rezabrutinib)
Wayrilz (Rezabrutinib) is a novel Bruton's Tyrosine Kinase (BTK) inhibitor. Approved in the United States in 2025, it is indicated for the treatment of persistent or chronic immune thrombocytopeni...
What Are the Side Effects of Wayrilz (Rezabrutinib)?
Wayrilz (Rezabrutinib) is an oral Bruton's Tyrosine Kinase inhibitor. Approved by the U.S. FDA in 2025, it is indicated for the treatment of persistent or chronic immune thrombocytopenia in adults...
Related Articles
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...
What Are the Indications for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of advanced breast cancer with specific gene mutations. As an estrogen receptor antagonist...
What Are the Purchase Channels for Elacestrant (Orserdu)?
With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific gene mutations, has brought new treatment options for patients. As the first oral sel...
Adverse Reactions of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer harboring MET gene mutations. By precisely inhibiting the act...
What are the Precautions for Capmatinib (Tabrecta) Administration?
Capmatinib (Tabrecta) is a targeted therapy drug for MET gene mutations, demonstrating significant efficacy in the treatment of advanced malignancies such as non-small cell lung cancer.What are the Pr...
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved